

Global Cancer Gene Therapy Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

<https://marketpublishers.com/r/GD306353419EN.html>

Date: November 2017

Pages: 209

Price: US\$ 4,400.00 (Single User License)

ID: GD306353419EN

Abstracts

Cancer Gene Therapy Market

Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, Lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.

The Global cancer gene therapy market is segmented on the basis of type, therapy, end-user and regional

Based on the type, global cancer gene therapy market is segmented as:

Gene Induced Immunotherapy

Tumour Antigen Gene Delivery

Cytokine Gene Delivery

Oncolytic Virotherapy

Adenoviruses

Adeno Associated Virus

Lentiviruses

Alpha Virus

Retrovirus

Herpes Simplex Virus

Vaccinia virus

Simian Virus

Gene Transfer/Gene Replacement

Electroporation

Magnetofection

Naked/Plasmid Vectors

Gene Gun

Sonoporation

Based on the therapy, global cancer gene therapy market is segmented as:

Retroviral Therapy

Adenoviral Therapy

Based on the end-user, global cancer gene therapy market is segmented as:

Hospitals

Oncology institutes

Biotechnological companies

Clinical Research Labs

Global cancer gene therapy market is highly fragmented with small biotech firms holding a chunk of the overall industry share. Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining a strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy. As per WHO, cancer incidence is projected to rise by 50% to reach 15 Mn by the end of this decade. This alarming increase in the number of patients and side effects associated with various chemotherapy drugs necessitates this as a potential treatment approach addressing the growing global burden of the cancers. Small biotech firms dominate the global cancer gene therapy market than the bigger players. The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases. Increased in the adoption of emerging genomic technologies such as Next Generation Sequencing (NGS) and high-density microarray coupled with favorable government initiatives will fuel global cancer gene therapy market. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance.

Geographically, the cancer gene therapy is segmented into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa. North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand. The U.K. market is anticipated to grow rapidly over the forecast period due to the rising occurrence of cancer along with the

increase in acceptance of gene technology. Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for cancer gene therapy market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding.

Some of the major companies operating in the global cancer gene therapy market are Urogen Pharmaceuticals Inc. (U.S), GenVec.Inc (U.S), Oxford BioMedica (U.K), Vical (U.S), ANI Pharmaceuticals, Inc. (U.S), and Genzyme Corporation (U.S). Novartis AG (Switzerland), and Cell Medica (U.K.)

In July 2017, Novartis received U.S. FDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.

In June 2017, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult's GMP manufacturing facility in Stevenage, UK.

In June 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies,

regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CANCER GENE THERAPY MARKET INTRODUCTION

2.1. Global Cancer Gene Therapy Market – Taxonomy

2.2. Global Cancer Gene Therapy Market –Definitions

2.2.1. Type

2.2.2. Therapy

2.2.3. End User

3. GLOBAL CANCER GENE THERAPY MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Cancer Gene Therapy Market Dynamics – Factors Impact Analysis

3.6. Global Cancer Gene Therapy Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Cancer Gene Therapy Market – Product Innovations

4. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL CANCER GENE THERAPY MARKET, BY TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Gene Induced Immunotherapy

5.1.1. Tumour Antigen Gene Delivery

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Cytokine Gene Delivery

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.2. Oncolytic Virotherapy

5.2.1. Adenoviruses

5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.1.3. Market Opportunity Analysis

5.2.2. Adeno Associated Virus

5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.2.3. Market Opportunity Analysis

5.2.3. Lentiviruses

5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.3. Market Opportunity Analysis

5.2.4. Alpha Virus

5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.4.3. Market Opportunity Analysis

5.2.5. Retrovirus

5.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.5.3. Market Opportunity Analysis

5.2.6. Herpes Simplex Virus

5.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.6.3. Market Opportunity Analysis

5.2.7. Vaccinia virus

5.2.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.7.3. Market Opportunity Analysis

5.2.8. Simian Virus

5.2.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.8.3. Market Opportunity Analysis

5.3. Gene Transfer/Gene Replacement

5.3.1. Electroporation

5.3.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.1.3. Market Opportunity Analysis

5.3.2. Magnetofection

5.3.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.2.3. Market Opportunity Analysis

5.3.3. Naked / Plasmid Vectors

5.3.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.3.3. Market Opportunity Analysis

5.3.4. Gene Gun

5.3.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.4.3. Market Opportunity Analysis

5.3.5. Sonoporation

5.3.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.5.3. Market Opportunity Analysis

6. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Retroviral Therapy

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Adenoviral Therapy

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

7. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals

7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Oncology institutes

7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Biotechnological companies

7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

7.4. Clinical Research Labs

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.4.3. Market Opportunity Analysis

8. GLOBAL CANCER GENE THERAPY MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User, and Region, 2017 – 2023

9. NORTH AMERICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Gene Induced Immunotherapy

9.1.1.1.1. Tumour Antigen Gene Delivery

9.1.1.1.2. Cytokine Gene Delivery

9.1.1.2. Oncolytic Virotherapy

9.1.1.2.1. Adenoviruses

9.1.1.2.2. Adeno Associated Virus

9.1.1.2.3. Lentiviruses

9.1.1.2.4. Alpha Virus

9.1.1.2.5. Retrovirus

9.1.1.2.6. Herpes Simplex Virus

9.1.1.2.7. Vaccinia virus

9.1.1.2.8. Simian Virus

9.1.1.3. Gene Transfer/ Gene Replacement

9.1.1.3.1. Electroporation

9.1.1.3.2. Magnetofection

9.1.1.3.3. Naked / Plasmid Vectors

9.1.1.3.4. Gene Gun

9.1.1.3.5. Sonoporation

9.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1.1. Retroviral Therapy

9.1.2.1.2. Adenoviral Therapy

9.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospitals

9.1.3.2. Oncology institutes

9.1.3.3. Biotechnological companies

9.1.3.4. Clinical Research Labs

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023

9.1.6. North America Cancer Gene Therapy Market Dynamics – Trends

10. EUROPE CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Gene Induced Immunotherapy

10.1.1.1.1. Tumour Antigen Gene Delivery

10.1.1.1.2. Cytokine Gene Delivery

10.1.1.2. Oncolytic Virotherapy

10.1.1.2.1. Adenoviruses

10.1.1.2.2. Adeno Associated Virus

10.1.1.2.3. Lentiviruses

10.1.1.2.4. Alpha Virus

10.1.1.2.5. Retrovirus

10.1.1.2.6. Herpes Simplex Virus

10.1.1.2.7. Vaccinia virus

10.1.1.2.8. Simian Virus

10.1.1.3. Gene Transfer/ Gene Replacement

10.1.1.3.1. Electroporation

10.1.1.3.2. Magnetofection

- 10.1.1.3.3. Naked / Plasmid Vectors
- 10.1.1.3.4. Gene Gun
- 10.1.1.3.5. Sonoporation
- 10.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.2.1.1. Retroviral Therapy
 - 10.1.2.1.2. Adenoviral Therapy
- 10.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.3.1. Hospitals
 - 10.1.3.2. Oncology institutes
 - 10.1.3.3. Biotechnological companies
 - 10.1.3.4. Clinical Research Labs
- 10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 10.1.4.1. Germany
 - 10.1.4.2. UK
 - 10.1.4.3. France
 - 10.1.4.4. Spain
 - 10.1.4.5. Italy
 - 10.1.4.6. Russia
 - 10.1.4.7. Poland
 - 10.1.4.8. Rest of Europe
- 10.1.5. Europe Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
- 10.1.6. Europe Cancer Gene Therapy Market Dynamics – Trends

11. ASIA-PACIFIC CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 11.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.1.1.1. Gene Induced Immunotherapy
 - 11.1.1.1.1. Tumour Antigen Gene Delivery
 - 11.1.1.1.2. Cytokine Gene Delivery
 - 11.1.1.2. Oncolytic Virotherapy
 - 11.1.1.2.1. Adenoviruses
 - 11.1.1.2.2. Adeno Associated Virus
 - 11.1.1.2.3. Lentiviruses

- 11.1.1.2.4. Alpha Virus
- 11.1.1.2.5. Retrovirus
- 11.1.1.2.6. Herpes Simplex Virus
- 11.1.1.2.7. Vaccinia virus
- 11.1.1.2.8. Simian Virus
- 11.1.1.3. Gene Transfer/ Gene Replacement
 - 11.1.1.3.1. Electroporation
 - 11.1.1.3.2. Magnetofection
 - 11.1.1.3.3. Naked / Plasmid Vectors
 - 11.1.1.3.4. Gene Gun
 - 11.1.1.3.5. Sonoporation
- 11.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.2.1.1. Retroviral Therapy
 - 11.1.2.1.2. Adenoviral Therapy
- 11.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 11.1.3.1. Hospitals
 - 11.1.3.2. Oncology institutes
 - 11.1.3.3. Biotechnological companies
 - 11.1.3.4. Clinical Research Labs
- 11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 11.1.4.1. Japan
 - 11.1.4.2. China
 - 11.1.4.3. India
 - 11.1.4.4. ASEAN
 - 11.1.4.5. Australia & New Zealand
 - 11.1.4.6. Rest of Asia-Pacific
- 11.1.5. Asia-Pacific Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User r and Country, 2017 – 2023
- 11.1.6. Europe Cancer Gene Therapy Market Dynamics – Trends

12. LATIN AMERICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 12.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 12.1.1.1. Gene Induced Immunotherapy
 - 12.1.1.1.1. Tumour Antigen Gene Delivery
 - 12.1.1.1.2. Cytokine Gene Delivery
- 12.1.1.2. Oncolytic Virotherapy
 - 12.1.1.2.1. Adenoviruses
 - 12.1.1.2.2. Adeno Associated Virus
 - 12.1.1.2.3. Lentiviruses
 - 12.1.1.2.4. Alpha Virus
 - 12.1.1.2.5. Retrovirus
 - 12.1.1.2.6. Herpes Simplex Virus
 - 12.1.1.2.7. Vaccinia virus
 - 12.1.1.2.8. Simian Virus
- 12.1.1.3. Gene Transfer/ Gene Replacement
 - 12.1.1.3.1. Electroporation
 - 12.1.1.3.2. Magnetofection
 - 12.1.1.3.3. Naked / Plasmid Vectors
 - 12.1.1.3.4. Gene Gun
 - 12.1.1.3.5. Sonoporation
- 12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.2.1.1. Retroviral Therapy
 - 12.1.2.1.2. Adenoviral Therapy
- 12.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.3.1. Hospitals
 - 12.1.3.2. Oncology institutes
 - 12.1.3.3. Biotechnological companies
 - 12.1.3.4. Clinical Research Labs
- 12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
 - 12.1.4.1. Brazil
 - 12.1.4.2. Mexico
 - 12.1.4.3. Argentina
 - 12.1.4.4. Venezuela
 - 12.1.4.5. Rest of Latin America
- 12.1.5. Latin America Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023
- 12.1.6. Latin America Cancer Gene Therapy Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CANCER GENE THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Gene Induced Immunotherapy

13.1.1.1.1. Tumour Antigen Gene Delivery

13.1.1.1.2. Cytokine Gene Delivery

13.1.1.2. Oncolytic Virotherapy

13.1.1.2.1. Adenoviruses

13.1.1.2.2. Adeno Associated Virus

13.1.1.2.3. Lentiviruses

13.1.1.2.4. Alpha Virus

13.1.1.2.5. Retrovirus

13.1.1.2.6. Herpes Simplex Virus

13.1.1.2.7. Vaccinia virus

13.1.1.2.8. Simian Virus

13.1.1.3. Gene Transfer/ Gene Replacement

13.1.1.3.1. Electroporation

13.1.1.3.2. Magnetofection

13.1.1.3.3. Naked / Plasmid Vectors

13.1.1.3.4. Gene Gun

13.1.1.3.5. Sonoporation

13.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1.1. Retroviral Therapy

13.1.2.1.2. Adenoviral Therapy

13.1.3. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospitals

13.1.3.2. Oncology institutes

13.1.3.3. Biotechnological companies

13.1.3.4. Clinical Research Labs

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Cancer Gene Therapy Market - Opportunity Analysis Index, By Type, Therapy, End User and Country, 2017 – 2023

13.1.6. MEA Cancer Gene Therapy Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Urogen Pharmaceuticals Inc. (U.S)

14.2.2. GenVec.Inc (U.S)

14.2.3. Oxford BioMedica (UK)

14.2.4. Vical (U.S)

14.2.5. ANI Pharmaceuticals, Inc. (U.S)

14.2.6. and Genzyme Corporation (U.S)

14.2.7. Novartis AG (Switzerland)

14.2.8. Cell Medica (UK)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Cancer Gene Therapy Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/GD306353419EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD306353419EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

